Yellowstone Biosciences

Executive Summary

Yellowstone Biosciences is a UK-based biotechnology company spun out of the University of Oxford, focused on discovering and developing a novel class of therapeutically targetable antigens that are frequently expressed in cancers, with an initial focus on acute myeloid leukemia (AML). Founded in 2017, the company is built on the foundational research of Professor Paresh Vyas and is backed by Syncona, a leading life sciences investment firm. Yellowstone aims to address the significant unmet need in AML and other cancers by leveraging its proprietary platform to identify antigens that are both highly prevalent and amenable to therapeutic targeting, potentially enabling treatments with improved efficacy and safety profiles. As a private, early-stage company, Yellowstone is likely advancing its lead programs toward preclinical development and IND-enabling studies, with the goal of entering clinical trials in the near term. The company's progress and valuation potential depend on successful validation of its antigen discovery platform and eventual clinical data.

Upcoming Catalysts (preview)

• Q2 2026Lead program IND filing for AML therapy40% success
• Q3 2026Publication of preclinical data demonstrating antigen target validation70% success
• Q4 2026Series A or B financing round to support clinical development60% success